Amid the surging novel coronavirus cases in India, the country’s ‘first’ indigenous COVID-19 vaccine COVAXIN has got the nod for human clinical trials from the Drug Controller General of India (DGCI). The drug has been developed by Hyderabad-based Bharat Biotech. The inactivated vaccine has shown promise in preclinical studies, demonstrating extensive safety and effective immune responses.
Follow us:
Website:
Facebook:
Twitter:
Instagram:
#moneycontrol
